These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 20356584)
21. Letrozole in second-line therapy of advanced breast cancer: more questions than answers. Mackey JR; Joy AA J Clin Oncol; 2001 Dec; 19(23):4353-5. PubMed ID: 11731524 [No Abstract] [Full Text] [Related]
22. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883 [TBL] [Abstract][Full Text] [Related]
23. Letrozole after tamoxifen for breast cancer--what is the price of success? Bryant J; Wolmark N N Engl J Med; 2003 Nov; 349(19):1855-7. PubMed ID: 14551339 [No Abstract] [Full Text] [Related]
24. Uterine metastasis of lobular breast cancer during adjuvant letrozole therapy. Komeda S; Furukawa N; Kasai T; Washida A; Kobayashi H J Obstet Gynaecol; 2013 Jan; 33(1):99-101. PubMed ID: 23259900 [No Abstract] [Full Text] [Related]
25. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?]. Gamucci T Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201 [No Abstract] [Full Text] [Related]
26. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302 [TBL] [Abstract][Full Text] [Related]
27. The Letrozole Breast Cancer Trial: clinical implications and remaining questions. Chen WY; Manson JE Womens Health Issues; 2004; 14(1):7-10. PubMed ID: 15001182 [No Abstract] [Full Text] [Related]
28. [Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer]. Tsukagoshi S Gan To Kagaku Ryoho; 2006 Jun; 33(6):859-63. PubMed ID: 16770112 [TBL] [Abstract][Full Text] [Related]
29. The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98. Monnier A Breast; 2006 Feb; 15 Suppl 1():S21-9. PubMed ID: 16500237 [TBL] [Abstract][Full Text] [Related]
30. Breast cancer survivors. Boyle F; Forbes J Aust Fam Physician; 2008 Oct; 37(10):791. PubMed ID: 19013826 [No Abstract] [Full Text] [Related]
31. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902 [TBL] [Abstract][Full Text] [Related]
32. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730 [TBL] [Abstract][Full Text] [Related]
33. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. Wasan KM; Goss PE; Pritchard PH; Shepherd L; Tu D; Ingle JN Breast Cancer Res Treat; 2012 Dec; 136(3):769-76. PubMed ID: 23089983 [TBL] [Abstract][Full Text] [Related]
34. Understanding the BIG results: Insights from the BIG 1-98 trial analyses. Wardley AM Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768 [TBL] [Abstract][Full Text] [Related]
35. A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole. Nasu K; Tsuno A; Takai N; Narahara H Arch Gynecol Obstet; 2009 Feb; 279(2):255-7. PubMed ID: 18523791 [TBL] [Abstract][Full Text] [Related]
36. False shortening of time to progression in letrozole 2.5-mg dose? Cocconi G J Clin Oncol; 2001 Dec; 19(23):4353; author reply 4354-5. PubMed ID: 11731525 [No Abstract] [Full Text] [Related]
37. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Cohen MH; Johnson JR; Li N; Chen G; Pazdur R Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893 [TBL] [Abstract][Full Text] [Related]
38. [CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer]. Nomura Y; Tominaga T; Enomoto K; Aoyama H; Nakamura Y; Abe R; Sano M; Nomizu T; Tohge T; Takashima S; Ohashi Y Gan To Kagaku Ryoho; 2002 Apr; 29(4):551-62. PubMed ID: 11977539 [TBL] [Abstract][Full Text] [Related]
39. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231 [TBL] [Abstract][Full Text] [Related]
40. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Carpenter R; Doughty JC; Cordiner C; Moss N; Gandhi A; Wilson C; Andrews C; Ellis G; Gui G; Skene AI Breast Cancer Res Treat; 2014 Apr; 144(3):569-76. PubMed ID: 24562823 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]